Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia

Drug and Alcohol Review

Volumn 28, Issue 4, 2009, Pages 447-454

  Vicknasingam, Balasingam ^a   Narayanan, Suresh ^a   Navaratnam, Visweswaran ^a  

^a SCHOOL OF PHYSICS   (Malaysia)

Author keywords

Drug users not in treatment; Hepatitis C; Malaysia; Risk behaviour; Risk factor

Indexed keywords

ADDICTION; ADOLESCENT; ADULT; ARTICLE; BISEXUALITY; CROSS-SECTIONAL STUDY; DISEASE TRANSMISSION; DRUG ABUSE; FEMALE; HEPATITIS C; HEROIN DEPENDENCE; HIGH RISK BEHAVIOR; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; MALAYSIA; MALE; PREVALENCE; PREVENTIVE HEALTH SERVICE; RISK FACTOR; SEXUAL BEHAVIOR; STATISTICS; SUBSTANCE ABUSE; URBAN POPULATION;

ADOLESCENT; ADULT; BISEXUALITY; CROSS-SECTIONAL STUDIES; DATA COLLECTION; FEMALE; HEPATITIS C; HEROIN DEPENDENCE; HIV INFECTIONS; HOMOSEXUALITY; HUMANS; MALAYSIA; MALE; NEEDLE SHARING; NEEDLE-EXCHANGE PROGRAMS; PREVALENCE; RISK FACTORS; RISK-TAKING; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS; URBAN POPULATION; YOUNG ADULT;

EID: 70349336807     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/j.1465-3362.2009.00087.x     Document Type: Article

References (39)

1. Aceijas C, Rhodes T. Global estimates of HCV infection among injecting drug users. Int J Drug Policy 2007;18: 352-8.
2. Verucchi G, Claza R, Manfredi R, Chiodo F. Human immunodeficiency virus and hepatitis C virus coinfection epidemiology, natural history, therapeutic options and clinical management. Infection 2004;33:33-46.
3. Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 2008;372:321-32.
4. Agensi Anti-Dadah Kebangsaan (AADK). Laporan Dadah, 2007; 3, January-September. Kuala Lumpur, Malaysia: Agensi Anti-Dadah Kebangsaan [National Antidrug Agency], 2007.
5. Ministry of Health. Speech ofYB Datuk Seri Dr Chua Soi Lek, Minister of Health, Malaysia, at the United Nations World AIDS Day 2006 Commemoration, Kuala Lumpur, 30 November 2006. Available at: http://www.moh.gov.my/MohPortal/DownloadServlet?id=1047&type=2 (accessed 7 April 2008).
6. Ministry of Health. Speech ofYB Datuk Seri Dr Chua Soi Lek, Minister of Health, Malaysia, at the opening ceremony and launch of clinical practice guidelines, Liver update 2007, 12 July 2007. Available at http://www.moh.gov.my/MohPortal/DownloadServlet?id=411&type=2 (accessed 7 April 2008).
7. Davies HTO, Crombie IK, Tavakoli M. When can odds ratios mislead? BMJ 1998;316:989-91.
8. Holcomb WL Jr, Chaiworapongsa T, Luke DA, Burgdorf KD. An odd measure of risk: use and misuse of the misuse of the odds ratio. Obstet Gynecol 2001;98:685-8.
9. Zhang J, Yu K. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. J Am Med Assoc 1998;280:1690-1.
10. Vicknasingam B, Navaratnam V. The use of rapid assessment methodology to complement existing national assessment and surveillance data: a study among injecting drug users in Penang, Malaysia. Int J Drug Policy 2008; 19:90-3.
11. Darke S, Ross J, Kaye S. Physical injecting sites among injecting drug users in Sydney, Australia. Drug Alcohol Depend 2001;62:77-82.
12. Miller PG, Lintzeris N, Forzisi L. Is groin injecting an ethical boundary for harm reduction? Int J Drug Policy 2008;19:486-91.
13. Agrest A, Finlay B. Statistical methods for the social sciences. Upper Saddle River, NJ: Prentice Hall, 1999.
14. Fuchs T, Wβmann L. Computer and student learning: bivariate and multivariate evidence on the availability and use of computers at home and at school. Brussels Econ Rev 2004;47:359-85. Available at http://www.res.org.uk/econometrics/504.pdf (accessed 30 December 2008).
15. Willner-Reid J, Belendiuk KA, Epstein DH, Schmittner J, Preston KL. Hepatitis C and human immunodeficiency virus risk behaviours in polydrug users on methadone maintenance. J Subst Abuse Treat 2008;35:78-86.
16. Jittiwutikarn J, Thongsawat S, Suryanon V, et al. Hepatitis C infection among drug users in Northern Thailand. Am J Trop Med Hyg 2006;74:1111-16.
17. Armstrong G, Wasley A, Simmard E, McQuillan G, Kuhnert W, Alter M. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14.
18. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2007; 155:645-53.
19. Xia X, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injecting drug users in China: systematic review and meta-analysis. Public Health 2008;122:990-1003.
20. Das HK, Borkakoty BJ, Mahanta J, Mehdi GK, Chellenge PK. Hepatitis C virus infection and risk behaviours among injecting drug users of Nagaland. Indian J Gastroenterol 2007;26:253-4.
21. Hajiani E, Hashemi J, Masjedizadeh R, Shayesteh AA, Idani E, Rajabi T. Seroepidemiology of hepatitis C and its risk factors in Khuzestan Province, south-west of Iran: a case-control study. World J Gastroenterol 2006;14:4884-7.
22. Choy Y, Gittens-Williams L, Apuzzio J, Skurnick J, Zollicoffer C, McGovern PG. Risk factors for hepatitis C infection among sexually transmitted disease-infected, inner city obstetric patients. Infect Dis Obstet Gynecol 2003;11: 191-8.
23. Garten RJ, Zhang J, Lai S, Liu W, Chen J, Yu XF. Coinfection with HIV and hepatitis C virus among injection drug users in southern China. Clin Infect Dis 2005; 41(Suppl. 1):S18-24.
24. Zhao M, Du J, Lu GH, Wang QY, Xu H, Zhu M. HIV sexual risk behaviours among injection drug users in Shanghai. Drug Alcohol Depend 2006;82(Suppl. 1):S43-7.
25. Evans JL, Hahn JA, Page-Shafer K, et al. Gender differences in sexual and injection risk behaviour among active young injection drug users in San Francisco (the UFO Study). J Urban Health 2003;80:137-46.
26. Carruthers SJ. Preventing hepatitis C: what do positive injectors do? Drug Alcohol Rev 2005;24:193-8.
27. Bluthenthal RN, Anderson R, Flynn NM, Kral AH. Higher syringe coverage is associated with lower odds of HIV risk and does not increase unsafe syringe disposal among syringe exchange program clients. Drug Alcohol Depend 2007;89:214-22.
28. Deren S, Fuller C, Pouget ER, et al. Impact of expanding syringe access in NewYork on sources of syringes for injection drug users in Harlem and Bronx, NYC, USA. Int J Drug Policy 2003;14:373-9.
29. Craine N, Walker M, Carnwath T, Klee H. Hepatitis C testing and injecting risk behaviour: the results of a UK based pilot study. Int J Drug Policy 2004;15:115-22.
30. Birkhead GS, Klein SJ, Candelas AR, et al. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach. Int J Drug Policy 2007;18:423-35.
31. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001;91: 42-6.
32. Gaskin S, Brazil C, Pickering D. The sharing of injecting paraphernalia by intravenous drug users (IDUs) within Worcestershire cohort, with specific reference to water and filters. Int J Drug Policy 2000;11:423-35.
33. Shapatava E, Nelson KE, Tsertsvadze T, del Rio C. Risk behaviours and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia. Drug Alcohol Depend 2006;82(Suppl. 1): S35-8.
34. Vidal-Trecan G, Coste J, Varesccon-Pousson I, Christoforov B, Boissonnaso A. HIV status knowledge and risk behaviours among intravenous drug users. Eur J Epidemiol 16:439-45.
35. Patrick DM, Tyndall MW, Cornelisse PGA, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. Canad Med Assoc J 2001;165:889-94.
36. Neaigus A, Gyarmathy VA, Miller M, et al. Injecting and sexual risk correlates of HBV, HCV seroprevalence among new drug injectors. Drug Alcohol Depend 2007;89:234-43.
37. Maher L, Jiong L, Jalaludin B, Chant KG, Kaldor JM. High hepatitis C incidence in new injecting drug users: a policy failure? Aust NZ J Public Health 2007;31:30-5.
38. Chang CJ, Lin CH, Lee CT, Chang SJ, Ko YC, Liu HW. Hepatitis C virus infection among short-term intravenous drug users in southern Taiwan. Eur J Epidemiol 1999;15: 597-601.
39. Mateu-Gelabert P, Treloar C, Calatayud VA, et al. How can hepatitis C be prevented in the long term? Int J Drug Policy 2007;18:388-40.